News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Boehringer Ingelheim Corporation Release: Benefits of Pradaxa® Maintained in Difficult to Treat Patients With Atrial Fibrillation and Symptomatic Heart Failure



7/16/2013 9:58:53 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Published in the European Journal of Heart Failure1, results from a new sub-analysis of the RE-LY®i trial demonstrate important benefits of Pradaxa® (dabigatran etexilate) over warfarin in difficult-to-treat patients with non-valvular atrial fibrillation (AF) and previous symptomatic heart failure (HF). The outcomes in heart failure patients were consistent with the results from the main RE-LY® trial: Pradaxa® 150mg twice daily reduced the risk of stroke including ischaemic stroke with similar rates of major bleeding compared to warfarin and Pradaxa® 110mg twice daily showed similar rates of stroke but significantly reduced major bleeding compared to warfarin. Importantly, both doses of Pradaxa® significantly reduced intracranial as well as total bleeding.1,2,3

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES